Animal models of co-infection  by Derouin, Francis et al.
N o t e s  a n d  C o m m e n t s  559 
3. Tauber MG, Sande MA. Pharmacodynamics of antibiotics in 
experimental bacterial meningitis--two sides to rapid bacterial 
killing in the cerebrospinal fluid. Scand J Infect Dis 1991; 
74(suppl): 173-8. 
4. Pfister HW, Fontana A, Tauber MG, Tomasz A, Scheld WM. 
Mechanisms of brain injury in bacterial meningitis: Workshop 
summary. Clin Infect Dis 1994; 19. 463-79. 
5. Kim YS, Sheldon RA, Elliot BR, Liu Q, Ferriero IIM, Tauber 
MG. Brain damage in neonatal meningitis caused by group B 
meptococci in rats. J Neuropathol Exp Neurol 1995; 54: 531-9. 
6. Nau R, Schmidt T, Tauber MG. Quinolone antibiotics in 
experimental pneumococcal meningitis in rabbits. Antirnicrob 
Agents Cheniother 1995; 3 9  593-7. 
Animal models of co-infection 
Clin Microbiol Infect 1998; 4: 55'3-562 
Francis Derouin I*, Claire Ldcroix *, Monique Brun-Pascaud ', FranGoise Chau ', 
Martine Sine$, Caroline Maslo and Pierre-Marie Girard3 
Laboratoire de Parasitologie-Mycologie, H6pital Saint-Louis, 1, Avenue Claude Vellefaux, 
75475, Paris Cedex 10, France; 'INSERM Unit6 13, H6pital Bichat-Claude Bernard, and 
3Service des Maladies Infectieuses, Hbpital Rothschild, Paris, France 
*Tel: +33 1 42 49 95 01 Fax: +33 1 42 49 48 03 E-mail: paracord@wanado.Fr 
INTRODUCTION 
During their lives, animals arid humans are usually 
co-infected with various micro-organisms, some of 
which remain latent for years. Several lines of evidence 
suggest that various interactions exist between the 
immune responses generated by different pathogens 
and that the pathogenesis of one infection may be 
markedly influenced by concurrent infection by another 
microorganism. 
Indeed, in vitro models have shown evidence of 
such interactions at a cellular level, especially for 
pathogens co-infecting the same cell compartment. 
However, animal models are needed the better to 
understand the process of host defense in cases of 
multiple infections, and to characterize the possible 
stimulating or wasting effects of the host responses 
against one microbial agent on the resistance or 
susceptibility to another. These models are also useful 
to examine the effect of therapy against one pathogen 
on the course of infection of associated pathogens, and 
assess the efficacy of antimicrobial agents for multiple 
therapy or prophylaxis. 
MODELS OF CO-INFECTION FOR PATHOGENIC 
STUDIES 
The interactions between the pathogens and the host 
are complex, and may be either direct, as seen when 
both microorganisms are intracellular, and/or indirect, 
through the inflammatory or immune responses gener- 
ated by each infectious agent. 
Several experiments have revealed the beneficial 
effect of co-infections: in various niodels of concurrent 
bacterial, protozoal and fungal infections, it has been 
shown that an infection by one pathogen could result 
in protection against a second microorganism. In some 
cases, this protection could be related to cross-reactivity 
and protective immunity between closely related 
microorganisms, raising the possibility of hetero- 
immunization or possible vaccination with non- 
virulent organisms. In other cases, the protection could 
be obtained with unrelated organisms, providing 
evidence of the role of non-specific immunity. For 
instance, this was shown in models of Cryptococcus 
neojorvnans infection in which partial resistance could be 
conferred by concurrent infection with Toxoplasma 
gondii [1] or Listeria [2]. We also noticed such 
interaction in a mouse model of concurrent chronic 
toxoplasma and Mycobacteriuvn avinm (MAI) infection 
in which co-infected mice presented with less clinical 
symptoms of illness than those infected by each agent 
alone, despite the fact that the kinetics of parasite 
burdens in brain and lungs and bacterial loads in lungs 
and spleen showed no difference between singly or 
dually infected mice. This was especially noted within 
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2-4 weeks postinfection, a period during which 
Xnxplasnza goridii predominantly involved the lungs, 
suggesting a possible interaction between the two 
pathogens on the local pulmonary immune or inflam- 
matory response (C. Maslo, unpublished) 
The recent concepts of the development of the 
cellular imniune response, based on the diiyerentiation 
of Thl  /Th2 lymphocytes and production of related 
cytokines, could partially explain such protection, since 
the promotion of a Th l  response by one infection 
could markedly influence the initial response against 
the second pathogen 131. 
On the other hand, there are many examples in 
which co-infections by different pathogens have a 
resulting deleterious effect on the host. For instance, 
the advent of virus-related immunosuppression may 
induce greater susceptibility to a chronic bacterial, 
niycotic or parasitic infection, resultiug in life-threaten- 
ing clinical manifestations, as seen in the course of 
AIDS. In the latter case, the predominant role of the 
virus-induced T-cell defect is well established, but the 
exact mechanism of this increased susceptibility is still 
poorly understood. 
In this context, aniiiial models of co-infection with 
iiiimunosuppressive viruses such as cytomegalovirus 
and LP-BM5 in mice, simian immunodeficiency virus 
in monkeys and feline immunodeficiency virus in cats 
have been developed to improve understanding of the 
pathogenesis of fungal or parasitic infections in virus- 
infected hosts. 
In the inurine inodel of AIDS (MAIDS), infection 
by LP-BM5 murine leukemia viruses results in pro- 
gressive immunodepression; this model has been 
extensively used to study dual infections with the 
main pathogens that may be a cause of opportunistic 
infections in AIDS patients: Cryptosporidinwi [4], M p -  
Iiacteriuni aviurn [5,6], Candida albicarrs [7], Leishmania 
[ 8,91, Zypanosorna cruzi [lO], and Toxoplasrna gondii 
[ 11 -131. Most of these studies revealed several aspects 
of interactions between the associated pathogens, usually 
with an increased susceptibility to the concurrent 
parasitic or mycotic infection, but also a marked effect 
on the course of viral disease. In our experience of co- 
infection with Tixoplasnrn p i d i i ,  we observed a weak 
increase in pulmonary parasitic loads in co-infected 
mice, but we found that Toxoplusnia gondii infection 
could influence the natural course of MAIDS, as the 
classical signs of progression of the viral infection (i.e. 
splenomegaly and lymphadenopathy) were significantly 
reduced in co-infected mice compared to mice infected 
with the virus alone. These results raised the possibility 
that cross-regulation between the T h l  cytokines, 
predominantly produced during Toxoplasina gondii 
infection, may have influenced the course of the viral 
disease, the progression of which is rather Th2 
dependent. Thus, our next objective was to examine 
the effect of a Th2 environment on the progression of 
viral infection. Indeed, earlier studies had already shown 
that a previous infection with Schistosoma marzsoni, a 
helniinthic parasite which predominantly induces a 
Th2 response at the onset and peak of the formation of 
granulomas around S. niansoni eggs, could alter the 
course of another coiicurrent infection. For instance. 
when mice susceptible to the nematode Triclinris nzuvis 
are co-infected with S. niunsorzi, the); acquire the 
capacity to resolve Eiclzrrris nirrris infection, and this 
capacity to expel Tviclturis inrrris is associated with the 
production ofTh2 cytokines [13]. In the same way, co- 
infection of Balb/c mice with S. nzanrorii and vaccinia 
virus led to a delayed clearance of the virus from the 
liver compared to that observed in mice infected with 
vaccinia virus alone [15], and this was related to the 
formation of granulomas around eggs of S. niarisoni i n  
the liver. However, in our study, which exanlined the 
effect of a previous S. inarirorzi infection on the course 
of MAIDS in C57 Bl/6 mice, we found exacerbation 
of the progression of the viral disease in co-infected 
mice, and the viral infection was found to have no 
effect on the development of liver granulomas induced 
by the eggs of S.  innnroni [16]. These experiments 
revealed that the proposed model of regulation of 
infections via the Thl-Th2 balance may represent a 
basis for coniprehension of the regulation of infections 
but is probably too simple to explain the variety and 
complexity of interactions arid cross-regulation that 
may exist in cases of concurrent infection. 
MODELS OF CO-INFECTION FOR PHARMACOLOGIC 
STUDIES 
Co-infections with viruses 
Although the models of co-infection with viruses 
have proved of major interest in the study of the 
pathogenesis of opportunistic infections and inter- 
actions with the course of viral disease, few pharnia- 
cologic applications have been developed to examine 
the preventive efficacy of drugs, directed against either 
the virus or the concurrent pathogen. However, onc 
remarkable example of the potential application of 
these models for drug studies is provided by experi- 
nients conducted in a niurine model of concurrent 
cytoniegalovirus- Exoplasrrro p w d i i  infections. In mice 
infected with E x o p l a s r m  goridii and then challenged by 
murine CMV (MCMV), toxoplasinosis reactivated and 
manifested as pneumonia, the severity of which was 
dependent on the infecting dose of MCMV [17]. By 
use of this niodel, it was shown that an antiviral drug 
(ganciclovir) could prevent the toxoplasma pulmonary 
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reactivation when administered before or early after the 
viral challenge, demonstrating the potential effect of 
antiviral therapy on the occurrence of opportunistic 
iiifections [ 18,191. 
Models of concurrent opportunistic infections 
Models of acute and chronic co-infections were 
developed in order to identifj new drugs or drug 
combinations that could be effective in the treatment 
and prevention of opportunistic infections. This experi- 
mental approach was justified by the frequency of 
concurrent infections in immurioconipromised patients 
(especially during AIDS), the fict that some drugs can 
be effective against several pathogens, and the lack of 
convenient in vitro models for such studies. 
For instance, Pneumocystis carinii cannot be grown 
in vitro, and for many years the rat model has been 
extensively used for experimental pneumocystosis. In 
parallel, murine models of single infection with 76x0- 
plasma gondii or mycobacteria are also currently being 
used for pharmacologic studies. Since latent I? carinii, 
Toxoplasma gondii and mycobacteria infections are 
frequently associated in immunodeficient patients, and 
since reactivation or exacerbation of these infections 
need to be concurrently prevented, we developed 
models of combined infections in immunocom- 
promised rats. The first model that was developed 
combined I? carinii pneumonia and acute toxoplasmosis 
in rats [20]. The administration of corticosteroids for 
5-7 weeks induced a reactivation of the naturally 
acquired I? carinii infection, causing a progressive 
pneumonia, and made the rats susceptible to Toxoplasma 
pndi i .  Thus, challenge with tachyzoites of the virulent 
RH strain of Toxoplasmu gondii results in acute 
toxoplasmosis which develops concurrently with I? 
carinii pneumonia. Without treatment or prophylaxis, 
rats die within 5 days after challenge with Toxoplasma 
gondii and present disseminated toxoplasmosis, involving 
spleen, lungs, liver and brain, ;associated with I? carinii 
pneumonia. By use of this model, the efficacy of drugs 
against both pathogens can be assessed by counting 
1? carinii cysts in the lung and titrating Toxoplasma gondii 
in tissues by subculture. This model was first used to 
confirm the efficacy of the combinations trimetho- 
prim-sulfamethoxazole and pyrimethamine-dapsone 
[20], and then to define the ratios of combined drugs 
which had optimum activity against both pathogens 
1211. Several other drugs were studied, administered 
either alone or in combination; atovaquone or 
roxithromycin administered alone offer only partial 
protection against I? carinii and Toxoplasma gondii 
(201 respectively, whereas PS--l5 (a new biguanide), 
epiroprim (an analog of trimetlioprim) combined with 
dapsone, and rifabutin combined with atovaquone 
were found to be effective for prevention of both 
infections [22]. 
More recently, this model was extended to include 
triple infection, with an additional infection by Myco- 
bacterium avium-intracellulare (MAI) initiated at the 
time of initiation of corticosteroid treatment. Infections 
were monitored by titration of each pathogen in its 
target organs. Thus, assessment of multiple prophylaxis 
against the three major pathogens encountered in 
AIDS patients was achieved, revealing the remarkable 
efficacy of the combination of clarithromycin and 
sulfamethoxazole for prevention of I? carinii, M. avium 
and Toxoplasma gondii infections [23]. 
These models, in which a partially resistant host 
becomes susceptible to infection because of its im- 
munosuppression, achieve a situation comparable to 
that observed in humans. Despite the fact that toxo- 
plasmosis or MA1 infections were not ‘naturally’ 
acquired or due to reactivation of previously acquired 
infections, these models were found to be relevant since 
they offer a unique opportunity to assess the effects of 
antimicrobial agents against three pathogens infecting 
an immunocompromised host. 
A murine model of chronic co-infection with 
Exoplasmn gondii and MA1 has also been used, mainly 
to identify drugs that could be used for eradication 
of latent infections [24]. This niodel differs from the 
rat model of co-infection in that non-immuno- 
compromised animals are used in order to obtain a non- 
lethal latent chronic infection by both pathogens. 
C57/B16 mice are concurrently infected with a non- 
virulent strain of Toxoplasma gondii and with M.  avium, 
but treatment is only initiated at the chronic phase, i.e. 
6 weeks after infection. The efficacy of rifabutin 
(which is effective against MA1 and Toxoplasma gondii] 
administered alone or in combination with atovaquone 
(which is effective against Toxoplasma gondii cysts and 
tachyzoites) has been examined; a synergistic effect of 
both drugs on Toxoplasma gondii brain cysts was demon- 
strated, with a more important reduction of parasitic 
burdens in concurrently infected mice than in mice 
infected with Toxoplasma gondii alone [24]. Further- 
more, the reduction of pulmonary MA1 loads observed 
in mice infected with MA1 alone was more pro- 
nounced and prolonged in co-infected mice. These 
results demonstrate an interaction between the two 
infections which could markedly interfere with the 
mode of action and efficacy of drugs. 
CONCLUSION 
From the different studies performed with animal 
models of double or triple infection there can be no 
doubt that these models will continue to play an 
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important role in the comprehension of the patho- 
genesis of rnicrobial infection arid investigation of 
millime responses (either specific or non-specific) 
against microorganisms. Furthermore, the pharma- 
cologic data provided by these models have already 
proved reliable for the design of therapeutic trials in 
humans and will contribute to the development of new 
strategies of combined prophylaxis or therapeutics. 
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